CDK9 and central nervous system neoplasm: While the unique anatomic and physiologic considerations for CNS tumors necessitate the selection of appropriate agents for adequate CNS delivery, our data supports the use of clinically-relevant CDK9 inhibitors in a multimodal treatment approach for these lethal cancers.